Evidence map›Paper›PMID 42847769›Full record

ArticleBriefings in bioinformatics2026

EPBAM: annotation-robust detection of alternative splicing events and a systematic benchmarking of current tools.

Cesar Lobato-Fernandez, Laura Jareno, Angel Rubio, Juan Angel Ferrer-Bonsoms

Abstract read
PubMed Publisher
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cesar Lobato-FernandezBiomedical Engineering and Science Department, TECNUN, University of Navarra, Paseo de Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Gipuzkoa, Spain.
Laura JarenoBiomedical Engineering and Science Department, TECNUN, University of Navarra, Paseo de Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Gipuzkoa, Spain.ORCID 0009-0003-2860-2222
Angel RubioBiomedical Engineering and Science Department, TECNUN, University of Navarra, Paseo de Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Gipuzkoa, Spain.ORCID 0000-0002-3274-2450
Juan Angel Ferrer-BonsomsBiomedical Engineering and Science Department, TECNUN, University of Navarra, Paseo de Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Gipuzkoa, Spain.ORCID 0000-0002-1588-2195

Funding

AECCAIRC PIBA_2020_1_0055Cancer Research UK C355/A26819Synlethal Project PID2019-110344RB-I00
6 · The paper itself

Abstract

Alternative splicing (AS) is a major driver of transcriptomic diversity, yet its computational analysis remains challenged by inconsistent event definitions across tools and by the sensitivity of quantification methods to annotation quality. Here, we present a comprehensive benchmark of seven AS detection tools-replicate Multivariate Analysis of Transcript Splicing (rMATS), Super-fast Pipeline for alternative splicing analysis, version 2 (SUPPA2), Modeling Alternative Junction Inclusion Quantification + Visualization Of Inferred Local splicing Alternatives (MAJIQ+VOILA), EventPointerST (EPST), Shiba, LeafCutter, and the newly introduced EventPointer BAM (EPBAM)-evaluated across three complementary datasets: reverse transcription PCR (RT-PCR) validated experiments, simulated data, and Lexogen Spike-In RNA Variant (SIRV). The inclusion of SIRV, which provide experimentally derived sequencing data with fully controlled ground truth, is central to our evaluation framework, enabling rigorous assessment of quantification accuracy under real technical conditions. We assess tool performance under three annotation scenarios-complete, incomplete, and overloaded-reflecting the annotation uncertainty commonly encountered in practice. EPBAM extends the EventPointer framework by enabling de novo event detection coupled with a coverage-corrected Ψ quantification strategy. Our results demonstrate that annotation quality substantially drives tool performance: annotation-dependent tools achieve peak accuracy under complete annotations, whereas EPBAM exhibits the most robust and consistent behaviour across annotation conditions, recovering unannotated events with low false discovery rates. No single tool dominates across all evaluation metrics, highlighting the importance of dataset diversity and standardized benchmarking practices for meaningful tool comparison in the AS field.

Indexed as

Alternative SplicingComputational BiologyMolecular Sequence AnnotationSoftwareBenchmarkingHumansalternative splicingbioinformaticsbootstrap based statisticsRNA splicingSIRV

Identifiers

PMID42847769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.